Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer

21 luglio 2011 aggiornato da: Southwest Oncology Group

Docetaxel (NSC-628503), Cisplatin (NSC-119875), And 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed By Accelerated Fractionation/Concomitant Boost Radiation And Concurrent Single Agent Cisplatin (NSC-119875), In Patients With Advanced Squamous Cell Head And Neck Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients with stage III or stage IV head and neck cancer.

Panoramica dello studio

Stato

Completato

Condizioni

Cancro testa e collo

Intervento / Trattamento

Descrizione dettagliata

OBJECTIVES:

Determine the overall survival of patients with stage III or IV squamous cell head and neck cancer treated with docetaxel, cisplatin, and fluorouracil followed by accelerated fractionation/concomitant boost radiotherapy and cisplatin.
Determine the unconfirmed complete response rate in these patients after treatment with induction chemotherapy.
Determine the overall complete response rate (confirmed and unconfirmed) in patients treated with this regimen.
Determine the toxic effects of this regimen in these patients.

OUTLINE:

Induction Chemotherapy: Patients receive docetaxel IV over 1 hour and cisplatin IV over 30-60 minutes on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity.
Chemoradiotherapy: Beginning within 3-4 weeks after administration of the second course of induction chemotherapy, patients receive accelerated fractionation radiotherapy once daily, 5 days per week, for 6 weeks with concomitant boost radiotherapy once daily, 5 days a week, for the last 2.5 weeks of radiotherapy. Patients also receive concurrent cisplatin IV over 30-60 minutes on days 1 and 22.

Patients are followed every 2 months for 1 year, every 3 months for 2 years, every 4 months for 1 year, and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 2 years.

Tipo di studio

Interventistico

Fase

Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

Canada
- Ontario
  - Toronto, Ontario, Canada, M5G 1X8
    - Hospital for Sick Children
Stati Uniti
- Alabama
  - Birmingham, Alabama, Stati Uniti, 35294-3300
    - University of Alabama at Birmingham Comprehensive Cancer Center
  - Mobile, Alabama, Stati Uniti, 36607
    - MBCCOP - Gulf Coast
- Arizona
  - Phoenix, Arizona, Stati Uniti, 85006-2726
    - CCOP - Western Regional, Arizona
  - Phoenix, Arizona, Stati Uniti, 85012
    - Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
  - Tucson, Arizona, Stati Uniti, 85723
    - Veterans Affairs Medical Center - Tucson
  - Tucson, Arizona, Stati Uniti, 85724
    - Arizona Cancer Center at University of Arizona Health Sciences Center
- Arkansas
  - Little Rock, Arkansas, Stati Uniti, 72205
    - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
  - Little Rock, Arkansas, Stati Uniti, 72205
    - Veterans Affairs Medical Center - Little Rock (McClellan)
- California
  - Duarte, California, Stati Uniti, 91010-3000
    - City of Hope Comprehensive Cancer Center
  - Fresno, California, Stati Uniti, 93720
    - California Cancer Center
  - Los Angeles, California, Stati Uniti, 90033
    - USC/Norris Comprehensive Cancer Center and Hospital
  - Martinez, California, Stati Uniti, 94553
    - Veterans Affairs Outpatient Clinic - Martinez
  - Oakland, California, Stati Uniti, 94609-3305
    - CCOP - Bay Area Tumor Institute
  - Orange, California, Stati Uniti, 92868
    - Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
  - Sacramento, California, Stati Uniti, 95817
    - University of California Davis Cancer Center
  - Santa Rosa, California, Stati Uniti, 95403
    - CCOP - Santa Rosa Memorial Hospital
  - Travis Air Force Base, California, Stati Uniti, 94535
    - David Grant Medical Center
- Colorado
  - Aurora, Colorado, Stati Uniti, 80010
    - University of Colorado Cancer Center at University of Colorado Health Sciences Center
  - Denver, Colorado, Stati Uniti, 80220
    - Veterans Affairs Medical Center - Denver
- District of Columbia
  - Washington, District of Columbia, Stati Uniti, 20060
    - MBCCOP - Howard University Cancer Center
- Florida
  - Tampa, Florida, Stati Uniti, 33612
    - Veterans Affairs Medical Center - Tampa (Haley)
- Georgia
  - Atlanta, Georgia, Stati Uniti, 30342-1701
    - CCOP - Atlanta Regional
- Hawaii
  - Honolulu, Hawaii, Stati Uniti, 96813
    - MBCCOP - Hawaii
- Illinois
  - Chicago, Illinois, Stati Uniti, 60612
    - Veterans Affairs Medical Center - Chicago (Westside Hospital)
  - Chicago, Illinois, Stati Uniti, 60612
    - MBCCOP - University of Illinois at Chicago
  - Decatur, Illinois, Stati Uniti, 62526
    - CCOP - Central Illinois
  - Hines, Illinois, Stati Uniti, 60141
    - Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
  - Maywood, Illinois, Stati Uniti, 60153-5500
    - Cardinal Bernardin Cancer Center at Loyola University Medical Center
- Kansas
  - Kansas City, Kansas, Stati Uniti, 66160-7353
    - Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
  - Wichita, Kansas, Stati Uniti, 67214-3882
    - CCOP - Wichita
  - Wichita, Kansas, Stati Uniti, 67218
    - Veterans Affairs Medical Center - Wichita
- Kentucky
  - Lexington, Kentucky, Stati Uniti, 40502-2236
    - Veterans Affairs Medical Center - Lexington
  - Lexington, Kentucky, Stati Uniti, 40536-0084
    - Markey Cancer Center at University of Kentucky Chandler Medical Center
- Louisiana
  - New Orleans, Louisiana, Stati Uniti, 70112
    - Veterans Affairs Medical Center - New Orleans
  - New Orleans, Louisiana, Stati Uniti, 70112
    - MBCCOP - LSU Health Sciences Center
  - New Orleans, Louisiana, Stati Uniti, 70112
    - Tulane Cancer Center at Tulane University Hospital and Clinic
  - Shreveport, Louisiana, Stati Uniti, 71130-3932
    - Louisiana State University Health Sciences Center - Shreveport
  - Shreveport, Louisiana, Stati Uniti, 71101-4295
    - Veterans Affairs Medical Center - Shreveport
- Massachusetts
  - Boston, Massachusetts, Stati Uniti, 02118
    - Cancer Research Center at Boston Medical Center
- Michigan
  - Ann Arbor, Michigan, Stati Uniti, 48105
    - Veterans Affairs Medical Center - Ann Arbor
  - Ann Arbor, Michigan, Stati Uniti, 48106
    - CCOP - Michigan Cancer Research Consortium
  - Ann Arbor, Michigan, Stati Uniti, 48109-0912
    - University Of Michigan Comprehensive Cancer Center
  - Detroit, Michigan, Stati Uniti, 48202
    - Josephine Ford Cancer Center at Henry Ford Hospital
  - Detroit, Michigan, Stati Uniti, 48201-1379
    - Barbara Ann Karmanos Cancer Institute
  - Detroit, Michigan, Stati Uniti, 48201-1932
    - Veterans Affairs Medical Center - Detroit
  - Grand Rapids, Michigan, Stati Uniti, 49503
    - CCOP - Grand Rapids
  - Royal Oak, Michigan, Stati Uniti, 48073-6769
    - CCOP - Beaumont
  - Southfield, Michigan, Stati Uniti, 48075
    - Providence Cancer Institute at Providence Hospital
- Mississippi
  - Jackson, Mississippi, Stati Uniti, 39216-4505
    - University of Mississippi Medical Center
  - Jackson, Mississippi, Stati Uniti, 39216
    - Veterans Affairs Medical Center - Jackson
- Missouri
  - Kansas City, Missouri, Stati Uniti, 64131
    - CCOP - Kansas City
  - Saint Louis, Missouri, Stati Uniti, 63141
    - CCOP - St. Louis-Cape Girardeau
  - Saint Louis, Missouri, Stati Uniti, 63110
    - St. Louis University Hospital Cancer Center
  - Springfield, Missouri, Stati Uniti, 65807
    - CCOP - Cancer Research for the Ozarks
- Montana
  - Billings, Montana, Stati Uniti, 59101
    - CCOP - Montana Cancer Consortium
- New Jersey
  - East Orange, New Jersey, Stati Uniti, 07018-1095
    - Veterans Affairs Medical Center - East Orange
- New Mexico
  - Albuquerque, New Mexico, Stati Uniti, 87108-5138
    - Veterans Affairs Medical Center - Albuquerque
  - Albuquerque, New Mexico, Stati Uniti, 87131
    - MBCCOP - University of New Mexico HSC
- New York
  - New York, New York, Stati Uniti, 10016
    - NYU School of Medicine's Kaplan Comprehensive Cancer Center
  - New York, New York, Stati Uniti, 10032
    - Herbert Irving Comprehensive Cancer Center at Columbia University
  - Rochester, New York, Stati Uniti, 14642
    - James P. Wilmot Cancer Center at University of Rochester Medical Center
- North Carolina
  - Salisbury, North Carolina, Stati Uniti, 28144
    - Veterans Affairs Medical Center - Salisbury
  - Winston-Salem, North Carolina, Stati Uniti, 27104-4241
    - CCOP - Southeast Cancer Control Consortium
- Ohio
  - Cincinnati, Ohio, Stati Uniti, 45220-2288
    - Veterans Affairs Medical Center - Cincinnati
  - Cincinnati, Ohio, Stati Uniti, 45267-0501
    - Charles M. Barrett Cancer Center at University Hospital
  - Cleveland, Ohio, Stati Uniti, 44195-9001
    - Cleveland Clinic Taussig Cancer Center
  - Columbus, Ohio, Stati Uniti, 43206
    - CCOP - Columbus
  - Dayton, Ohio, Stati Uniti, 45429
    - CCOP - Dayton
  - Dayton, Ohio, Stati Uniti, 45428-1002
    - Veterans Affairs Medical Center - Dayton
- Oregon
  - Portland, Oregon, Stati Uniti, 97207
    - Veterans Affairs Medical Center - Portland
  - Portland, Oregon, Stati Uniti, 97225
    - CCOP - Columbia River Oncology Program
  - Portland, Oregon, Stati Uniti, 97201-3098
    - Cancer Institute at Oregon Health and Science University
- South Carolina
  - Charleston, South Carolina, Stati Uniti, 29425
    - Hollings Cancer Center at Medical University of South Carolina
  - Charleston, South Carolina, Stati Uniti, 29401-5799
    - Veterans Affairs Medical Center - Charleston
  - Greenville, South Carolina, Stati Uniti, 29615
    - CCOP - Greenville
  - Spartanburg, South Carolina, Stati Uniti, 29303
    - CCOP - Upstate Carolina
- Tennessee
  - Memphis, Tennessee, Stati Uniti, 38104
    - University of Tennessee Cancer Institute
- Texas
  - Amarillo, Texas, Stati Uniti, 79106
    - Harrington Cancer Center
  - Amarillo, Texas, Stati Uniti, 79106
    - Veterans Affairs Medical Center - Amarillo
  - Fort Sam Houston, Texas, Stati Uniti, 78234-6200
    - Brooke Army Medical Center
  - Galveston, Texas, Stati Uniti, 77555-0565
    - University of Texas Medical Branch
  - Houston, Texas, Stati Uniti, 77030
    - Veterans Affairs Medical Center - Houston
  - Houston, Texas, Stati Uniti, 77030-4095
    - University of Texas - MD Anderson Cancer Center
  - San Antonio, Texas, Stati Uniti, 78229-3900
    - University of Texas Health Science Center at San Antonio
  - San Antonio, Texas, Stati Uniti, 78229
    - Veterans Affairs Medical Center - San Antonio (Murphy)
  - Temple, Texas, Stati Uniti, 76504
    - Veterans Affairs Medical Center - Temple
  - Temple, Texas, Stati Uniti, 76508
    - CCOP - Scott and White Hospital
- Utah
  - Salt Lake City, Utah, Stati Uniti, 84148
    - Veterans Affairs Medical Center - Salt Lake City
  - Salt Lake City, Utah, Stati Uniti, 84112-5550
    - Huntsman Cancer Institute
- Washington
  - Seattle, Washington, Stati Uniti, 98101
    - CCOP - Virginia Mason Research Center
  - Seattle, Washington, Stati Uniti, 98108
    - Veterans Affairs Medical Center - Seattle
  - Seattle, Washington, Stati Uniti, 98109
    - Puget Sound Oncology Consortium
  - Tacoma, Washington, Stati Uniti, 98431-5000
    - Madigan Army Medical Center
  - Tacoma, Washington, Stati Uniti, 98405-0986
    - CCOP - Northwest

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

DISEASE CHARACTERISTICS:

Histologically confirmed squamous cell carcinoma of the head and neck (excluding lip, nasopharynx, paranasal sinus, and salivary gland) by biopsy or fine needle aspirate of the primary lesion or neck mass
- Stage III or IV disease
No evidence of distant metastases
- Negative chest x-ray
Primary site in the head and neck region must be identified
- No unknown primary site
Considered to be appropriate for definitive radiotherapy with curative intent

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

Zubrod 0-1

Life expectancy

Not specified

Hematopoietic

Granulocyte count greater than 1,500/mm^3
Platelet count greater than 100,000/mm^3

Hepatic

Bilirubin no greater than upper limit of normal (ULN)
Alkaline phosphatase less than 2 times ULN
ALT or AST less than 1.5 times ULN

Renal

Creatinine less than 1.5 mg/dL

Cardiovascular

No myocardial infarction within the past 3 months
No unstable or uncontrolled angina

Other

Not pregnant or nursing
Fertile patients must use effective contraception
No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
No evidence of pre-existing peripheral neuropathy
No active systemic infection
No history of hypersensitivity reaction to products containing polysorbate 80

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

No prior chemotherapy

Endocrine therapy

Not specified

Radiotherapy

See Disease Characteristics
No prior radiotherapy

Surgery

No prior surgery for head or neck cancer

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Scopo principale: Trattamento

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Southwest Oncology Group

Collaboratori

National Cancer Institute (NCI)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck. 2010 Feb;32(2):221-8. doi: 10.1002/hed.21179.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 aprile 2003

Completamento primario (Effettivo)

1 novembre 2007

Date di iscrizione allo studio

Primo inviato

5 febbraio 2003

Primo inviato che soddisfa i criteri di controllo qualità

5 febbraio 2003

Primo Inserito (Stima)

6 febbraio 2003

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

25 luglio 2011

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 luglio 2011

Ultimo verificato

1 luglio 2011

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

CDR0000269781
U10CA032102 (Sovvenzione/contratto NIH degli Stati Uniti)
S0216 (Altro identificatore: SWOG)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .